Positive PD-L1 expression on the tumor surface serves as an indicator that a patient may be responsive to PD-1-PD-L1-targeting drugs, with CTLA-4 presence on T cells serving as a marker that a patient may be responsive to anti-CTLA-4 immunotherapeutic drugs [8,9]. This evidence concerns the gene CD274 and neoplasm.